D. pteronyssinus Dust Mite SCIT: The Molecular Biology Behind HDM Shots
Dermatophagoides pteronyssinus (European house dust mite) SCIT uses FDA-standardized 10,000 AU/mL extract targeting 7β12 Β΅g Der p 1 at maintenance. Der p 1 simultaneously breaches epithelial barriers, amplifies IgE (CD23 cleavage), suppresses Treg (CD25 cleavage), and activates PAR-2; Der p 2 substitutes for MD-2 in the TLR4 complex (Trompette 2009 Nature). Der p 23 predicts childhood-onset asthma and is missed by extract-based diagnostics in 4β5% of sensitized patients.
About Curexβs SCIT program
Curexβs at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- β’ Pollens β tree, grass, weed & ragweed
- β’ Pet dander β cat & dog
- β’ Dust mites
- β’ Molds β Alternaria & mold mix
D. pteronyssinus (European House Dust Mite)is covered here for general education and may not be part of Curexβs current treatment set. Join the waitlist and our care team will help confirm your options.
D. pteronyssinus (European House Dust Mite) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to d. pteronyssinus (european house dust mite) β rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of d. pteronyssinus (european house dust mite) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7β10 years.
There are two evidence-based forms of d. pteronyssinus (european house dust mite) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course β the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of d. pteronyssinus (european house dust mite) extract in a clinic, escalating over 3β6 months until a maintenance dose is reached. Continued monthly for 3β5 years. Longest clinical track record for d. pteronyssinus (european house dust mite) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50β100+ in-person clinic visits across the full course
- Or at home with no clinic visitsβ Curexβs Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing d. pteronyssinus (european house dust mite) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home β no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription d. pteronyssinus (european house dust mite) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots β protocol, efficacy data, side effects, and cost. If youβd rather skip the clinic and treat d. pteronyssinus (european house dust mite) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is D. pteronyssinus (European House Dust Mite)?
The biology, taxonomy, and clinical fingerprint of D. pteronyssinus (European House Dust Mite) β the foundation of how SCIT targets it.
Dermatophagoides pteronyssinus: Der p 1 cleaves tight junction proteins occludin, claudin-1, and ZO-1; Der p 2 substitutes for MD-2 in the TLR4 complex; Der p 23 coats fecal pellet peritrophic membranes and predicts childhood asthma.
- Scientific name
- Dermatophagoides pteronyssinus
- Family
- PyroglyphidaeHouse dust mite family
- Type
- Indoor dust mite β perennial aeroallergen via fecal pellets in bedding, carpets, and upholstery
- Native to
- Coastal and humid temperate environments worldwide; dominant species in the eastern US coastal states, Europe, and humid tropics
- Allergen proteins
- Der p 1 (cysteine protease, 24β25 kDa, 70β100% IgE reactivity) β major allergen; the most studied single allergen in allergy medicine (major)Der p 2 (NPC2/MD-2 homolog, 14 kDa, 80β100% IgE reactivity) β major allergen; auto-adjuvant TLR4 activity (major)Der p 23 (peritrophin-like, 8 kDa, 42β74% IgE reactivity) β major allergen; predicts childhood-onset asthma; absent from 13 of tested commercial extracts (major)Der p 10 (tropomyosin, 36β37 kDa, 5β18%) β pan-allergen cross-reacting with shrimp Pen a 1 and cockroach Bla g 7Der p 11 (paramyosin, 103 kDa, ~10% general / >50% in atopic dermatitis) β major in atopic dermatitis specifically39 allergen groups recognized through Der p 39
- Particle size
- 10β40 ΞΌm (fecal pellets carrying Der p 23 in peritrophic membrane); >95% of mite allergen is fecal-pellet-associated
- Avoidance difficulty
- Nearly impossible
How D. pteronyssinus (European House Dust Mite) Allergy Presents
Symptoms by body system β useful for distinguishing D. pteronyssinus (European House Dust Mite) sensitivity from overlapping allergies and infections.
Respiratory
- Perennial allergic rhinitis: nasal congestion, sneezing, and rhinorrhea year-round with autumn peak
- Asthma β Der p 2's TLR4 auto-adjuvant activity drives innate immune amplification; Sporik 1990 NEJM established the 10 Β΅g Der p 1/g threshold for acute asthma risk
- Chronic rhinosinusitis in patients with perennial uncontrolled HDM disease
- Nocturnal wheezing and coughing from concentrated mite allergen in mattresses and pillows
- Der p 23 IgE at age β€5 independently predicts school-age asthma development (Resch 2015 JACI)
Ocular
- Perennial allergic conjunctivitis with itching and watering β characteristic of year-round HDM sensitization
- Eye symptoms worst in autumn as mite populations peak post-summer
- Allergic shiners (periorbital darkening and edema) from chronic rubbing and inflammation
Dermal
- Atopic dermatitis flares β Der p 11 (paramyosin, 103 kDa) sensitizes >50% of atopic dermatitis patients but only ~10% of rhinitis-only patients
- Eczema exacerbation with increased indoor humidity that drives mite proliferation
- Urticaria from direct mite exposure (uncommon but documented)
Systemic
- Fatigue and sleep disruption from nocturnal respiratory symptoms and poor asthma control
- Reduced school and work performance from perennial uncontrolled rhinitis
- Shellfish allergy in Der p 10-sensitized patients via tropomyosin cross-reactivity with shrimp Pen a 1 (81% identity) and cockroach Bla g 7
Der p 23 is the allergen that changed how I think about dust mite diagnostics in children. It sensitizes 74% of HDM-allergic patients but is absent from 13 tested commercial extract products β meaning children with monosensitization to Der p 23 get a 'negative' dust mite test and never receive SCIT. When I see a child with asthma and weak or negative Der p 1/2 results, Der p 23 is the next molecule I test.
Where D. pteronyssinus (European House Dust Mite) Triggers Year-Round
D. pteronyssinus (European House Dust Mite) is a perennial trigger β exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial β D. pteronyssinus peaks in autumn in coastal humid regions; nocturnal symptoms characteristic year-roundΒ· Year-round with autumn peak; highest concentrations in bedroom bedding
US Exposure Map
21 high-intensity statesExposure intensity by state (text version)
- ME:
- High
- VT:
- High
- NH:
- High
- WA:
- High
- MT:
- Low
- ND:
- Low
- MN:
- Moderate
- WI:
- Moderate
- MI:
- Moderate
- NY:
- High
- MA:
- High
- OR:
- High
- ID:
- Moderate
- WY:
- Low
- SD:
- Low
- IA:
- Moderate
- IL:
- Moderate
- IN:
- Moderate
- OH:
- Moderate
- PA:
- Moderate
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- High
- NV:
- Moderate
- UT:
- Moderate
- CO:
- Moderate
- NE:
- Moderate
- MO:
- Moderate
- KY:
- Moderate
- WV:
- Moderate
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- Moderate
- AR:
- Moderate
- TN:
- Moderate
- NC:
- High
- SC:
- High
- OK:
- Moderate
- LA:
- High
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- Moderate
- FL:
- High
- AK:
- Low
- HI:
- Low
What D. pteronyssinus (European House Dust Mite) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
D. pteronyssinus shares ~85% IgE cross-reactivity with D. farinae via highly conserved Group 1 (cysteine protease) and Group 2 (NPC2/MD-2) allergen families; Der p 10 (tropomyosin) creates the pan-allergen bridge to shellfish and cockroach.
Standard US dual-species vial targeting 7β12 Β΅g Der p 1 + 7β12 Β΅g Der f 1 per injection
Der p 1 / Der f 1 share ~80% sequence identity; Der p 2 / Der f 2 share ~87β88%; Group 10 shares ~95%
Mite-Shellfish Cross-Reactivity via Der p 10
Der p 10 (tropomyosin, 36β37 kDa) shares 81% sequence identity with shrimp Pen a 1 and ~80% with cockroach Bla g 7. Over 70% of HDM-allergic patients show IgE to shrimp in some studies, with 55% reacting to shrimp tropomyosin specifically. Der p 10-specific IgE is the key biomarker for predicting clinical shellfish reactivity in dust-mite-allergic patients.
Is SCIT Right for Your D. pteronyssinus (European House Dust Mite) Allergy?
Answer 5 questions to assess whether D. pteronyssinus allergy shots are right for your year-round symptoms.
How severe are your dust mite allergy symptoms?
The D. pteronyssinus (European House Dust Mite) SCIT Protocol
D. pteronyssinus SCIT uses FDA-standardized 10,000 AU/mL extract; maintenance targets 7β12 Β΅g Der p 1 per injection per AAAAI/ACAAI Practice Parameters, reached over 3β6 months of weekly build-up.
Starting at 1:100,000 dilution (Curex begins more conservatively than the textbook 1:10,000), the Der p 1 dose is escalated once weekly toward the target maintenance concentration. A mandatory 30-minute post-injection observation period applies at every visit. Patients with poorly controlled asthma (FEV1 <70% predicted) should not receive injections on that day. Curex uses a conservative once-weekly build-up and does not offer rush or cluster schedules.
Maintenance injections maintain immune tolerance at target Der p 1 dose; the interval is set by the prescribing allergist. Benefits typically accumulate over the first 1β2 years of maintenance; PAT study showed lasting benefits 7 years after 3-year treatment. Component-resolved monitoring of Der p 23 may identify patients requiring supplementation with recombinant Der p 23 if monosensitization is identified.
Disease modification from 3β5 years of SCIT produces durable immunologic changes β reduced IgE, increased IgG4, Th1/Treg polarization β that typically persist years after stopping. Most allergists recommend 3β5 years before considering discontinuation.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for D. pteronyssinus (European House Dust Mite) SCIT
D. pteronyssinus SCIT is backed by the same landmark evidence base as D. farinae SCIT β they share the same extract pool and primary efficacy trials β with additional molecular evidence from the ODACTRA pivotal trials.
- HDM SCIT symptom score SMD vs placebo85%Kim JM et al. 2021, JACI Practice 9:4450 β network meta-analysis of 26 RCTs: SMD -1.669 (95% CI -2.7 to -0.639)
- Asthma exacerbation reduction (HDM SLIT-tablet asthma trial P014)33%Asthma trial P014, 834 European adults β 31β34% risk reduction; 42% vs 15% ICS reduction
- Pediatric TCRS reduction (MT-12 trial, ODACTRA)22%Nolte H et al. MT-12 trial, 1,460 children ages 5β11 β 22.0% relative reduction (95% CI 12.0β31.1, P<0.0001)
- Der p 23 IgE predicting asthma at school age (childhood cohort)74%Resch Y et al. 2015, JACI 136:1083 β Der p 23 IgE at age β€5 predicted school-age asthma; 74% IgE reactivity
D. pteronyssinus SCIT produces the largest symptom-score improvement across all allergen immunotherapy modalities (Kim 2021). Der p 1's four-front immune attack (barrier disruption, IgE amplification, Treg suppression, innate activation), Der p 2's TLR4 auto-adjuvant mechanism (Trompette 2009 Nature), and Der p 23's pediatric asthma prediction role (Resch 2015) together explain why Dermatophagoides allergy is particularly amenable to immunotherapy-mediated disease modification.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
D. pteronyssinus (European House Dust Mite) SCIT Side Effects
D. pteronyssinus SCIT has one of the best-characterized safety profiles in allergy practice due to decades of experience with FDA-standardized extract.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection site swelling Wheal and erythema peaking at 20β30 minutes; resolves within 24 hours; does not require dose reduction unless >25 mm | Rate 30β50% | Mild |
Injection site itching Expected local reaction; cold compress and topical antihistamine provide relief | Rate 20β40% | Mild |
Large local reaction Swelling >25 mm lasting >24 hours; requires dose reduction and allergist assessment at next visit | Rate 5β10% | Moderate |
Delayed local reaction Swelling appearing 6β24 hours post-injection; typically self-resolves without intervention | Rate 1β3% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare Sneezing and eye watering within 30 minutes; resolves with antihistamine | Rate 1β3% | Mild |
Urticaria Hives requiring antihistamine; epinephrine if systemic progression | Rate 0.1β0.5% | Mild |
Asthma exacerbation Bronchospasm during 30-minute observation; FEV1 β₯70% predicted required before each injection | Rate 0.1β0.5% | Moderate |
Anaphylaxis A prescribed epinephrine auto-injector is confirmed immediately on hand before the first injection, and with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff. | Rate < 0.01% per injection | Severe |
D. pteronyssinus SCIT has been administered for decades with an excellent safety record when standard protocols are followed. Poorly controlled asthma is the most important contraindication β FEV1 must be β₯70% predicted before each injection. Curex carries that record into at-home care: the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector is confirmed on hand, and a board-certified allergist oversees gradual, week-by-week dose escalation. (The ODACTRA SLIT-tablet is a separate FDA-approved option whose first dose is taken in-office with 30-minute observation.)
SCIT vs Alternatives for D. pteronyssinus (European House Dust Mite)
D. pteronyssinus-sensitized patients have four well-characterized options: SCIT (strongest efficacy evidence), ODACTRA SLIT-tablet (FDA-approved at-home alternative), environmental control, and pharmacotherapy.
| Criterion | At-home SCIT (Curex)Best | ODACTRA SLIT-tablet | Avoidance measures | Medications |
|---|---|---|---|---|
| Effectiveness | Excellent β SMD -1.669, largest in allergen IT literature | Good β 17β22% TCRS improvement; 31β34% asthma exacerbation reduction | Modest alone; significant when multicomponent (WAO 2024: RR 3.39) | Good for symptom suppression; no disease modification |
| 5-yr cost | $3,500β$12,000 over 5 years | Moderate β no office visit costs but tablet price varies | Low β $50β$300 one-time for encasings | $500β$2,000/yr ongoing |
| Duration | 3β5 years; weekly build-up then maintenance on allergist-set schedule | 3β5 years daily sublingual tablet | Ongoing β must be maintained indefinitely | Indefinite daily use |
| Convenience | At-home weekly self-injection with Curex; no clinic visits | Home-based daily after first in-office dose | Minimal lifestyle disruption | Daily pills and nasal sprays |
| Safety | USP <797> serum; Virtual Shot Roomβsupervised first/changed dose; epinephrine Rx on hand | Black-box warning; epinephrine Rx required | No treatment risks | Generally safe |
| Lasting effect | Disease-modifying; 7+ years lasting benefit | Disease modification documented | Effective only while maintained | No lasting effect after stopping |
At-home SCIT (Curex)Best
ODACTRA SLIT-tablet
Avoidance measures
Medications
For patients with confirmed D. pteronyssinus sensitization and inadequate pharmacotherapy response, SCIT is the most evidence-supported path to lasting disease modification. Curex's at-home blood testing panel includes Der p 1, Der p 2, and Der p 23 components individually β critical because Der p 23 is underrepresented in most commercial extracts and independently predicts pediatric asthma. Curex now delivers that same subcutaneous immunotherapy as an at-home allergy shot with pricing confirmed in a current program quote: a personalized Dermatophagoides serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation β so eligible patients get the disease-modifying modality without weekly clinic visits.
What D. pteronyssinus (European House Dust Mite) SCIT Actually Costs
Most major US insurers cover D. pteronyssinus SCIT under standard allergy benefits when ordered by a board-certified allergist with supporting diagnostic testing. ODACTRA SLIT-tablet coverage varies by plan and requires prior authorization. Out-of-pocket cost depends on deductible and co-insurance; verify with your insurer before starting.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your d. pteronyssinus (european house dust mite) allergy. Get a plan.
Take Curexβs 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you β shots or drops.
Free quiz Β· Board-certified allergists Β· 50,000+ patients treated Β· HSA/FSA eligible
D. pteronyssinus (European House Dust Mite) SCIT β Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Der p 23 is the third major allergen of D. pteronyssinus β a small (8 kDa) peritrophin-like protein found in the peritrophic membrane lining mite fecal pellets. Despite being present in tiny quantities (30-fold less mRNA expression than Der p 1), it elicits IgE in 74% of HDM-allergic patients (Weghofer 2013 J Immunol). Critically, approximately 4β5% of Der p 23-sensitized patients are monosensitized β they have IgE to Der p 23 but not to Der p 1 or Der p 2. Because Der p 23 is absent from 13 tested commercial HDM extract products, standard extract-based skin testing misses these patients entirely, leaving them with untreated asthma-predisposing sensitization. Resch 2015 JACI showed that Der p 23 IgE at age β€5 predicts school-age asthma development β making component-resolved testing for Der p 23 essential in any child with asthma and suspected HDM sensitization.
Der p 1 is a cysteine protease β an enzyme β and its enzymatic activity allows it to simultaneously disrupt immunity at four levels. First, it cleaves the tight junction proteins occludin, claudin-1, and ZO-1, increasing epithelial permeability so more allergen reaches subepithelial immune cells (Wan 1999 J Clin Invest). Second, it cleaves CD23 (FcΞ΅RII) from B cells, removing the negative feedback mechanism that normally limits IgE production, leading to uncontrolled IgE amplification (Schulz 1995/1997 Eur J Immunol). Third, it cleaves CD25 (IL-2RΞ±) from T cells, which are essential for Treg and Th1 propagation, pushing the immune response toward Th2 dominance β the allergic state (Schulz, Sewell & Shakib 1998 J Exp Med). Fourth, it activates PAR-2 on airway epithelial cells, triggering IL-6 and IL-8 release (Asokananthan 2002 J Immunol). No other known allergen attacks all four immune checkpoints simultaneously, which explains why HDM allergy is so persistent and difficult to manage without immunotherapy.
ODACTRA (ALK-AbellΓ³) is an FDA-approved sublingual tablet taken daily under the tongue at home after the first in-office dose with 30-minute observation. It contains standardized extracts of both D. pteronyssinus and D. farinae in a single 12 SQ-HDM dose β covering both Dermatophagoides species simultaneously. SCIT delivers the extract via subcutaneous injection and achieves a larger effect size on symptom scores (SMD -1.669 versus SLIT-tablet SMD -0.329 per Kim 2021). Those injections were traditionally given in a clinic during the 6-month build-up, but Curex now delivers the same subcutaneous immunotherapy as an at-home weekly shot β a USP <797> compounded serum with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff and a prescribed epinephrine auto-injector confirmed on hand. This at-home model is supported by safety data: a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities β lower than the 3%β14% typically seen with office-based shots. ODACTRA is approved for ages 5β65 and avoids injections; SCIT is preferred when the highest level of symptom reduction is the goal. The choice now comes down to whether you prefer an injection or a sublingual tablet, not clinic access. Both produce disease modification and lasting benefit after 3β5 years.
The evidence suggests yes β allergy immunotherapy, including dust mite SCIT, may reduce the risk of asthma development in children with allergic rhinitis. The PAT (Preventive Allergy Treatment) study randomized 205 children with pollen rhinoconjunctivitis to 3 years of SCIT or pharmacotherapy-only control and demonstrated sustained asthma prevention lasting 7 years after treatment cessation (OR 2.68; 95% CI 1.3β5.7 for asthma development in controls). A large retrospective cohort study (N=118,754) showed AIT reduced incident asthma risk by approximately 40% (RR 0.60; 95% CI 0.42β0.84). For children already sensitized to Der p 23 (which independently predicts asthma at school age per Resch 2015), starting HDM SCIT before asthma develops is a clinically reasonable strategy supported by existing evidence. A board-certified pediatric allergist can assess whether early intervention is appropriate for your child.
Co-sensitization to dust mites and shellfish is common and is often driven by Der p 10, the tropomyosin allergen in D. pteronyssinus that shares 81% sequence identity with shrimp Pen a 1 (shrimp tropomyosin). Over 70% of HDM-allergic patients show IgE to shrimp in some studies, with 55% specifically reactive to shrimp tropomyosin. Determining whether your shellfish reactivity is tropomyosin-driven (IgE against the conserved pan-allergen) or driven by other shrimp-specific proteins is clinically important. If your shrimp allergy is tropomyosin-based and you have Der p 10 IgE, some allergists theorize that controlling HDM sensitization through SCIT might reduce tropomyosin IgE levels β but this has not been demonstrated in trials. A board-certified allergist can test Der p 10 and shellfish tropomyosin-specific IgE to guide your clinical management.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs β including the parts that are not flattering.